Must not have received prior EBV or LMP-specific T cells within days of entry onto this study Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last months PRIOR TO registration\r\n* Transmural myocardial infarction within the last months prior to study entry\r\n* Unstable ventricular arrhythmia within the last months prior to study entry\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics within days prior to study entry\r\n* Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within days prior to study entry\r\n* Bleeding within days prior to study entry due to any cause, requiring transfusion\r\n* Thrombolytic therapy within days prior to study entry; subcutaneous heparin is permitted\r\n* Known bleeding or clotting disorder\r\n* Uncontrolled psychotic disorder Patients fulfilling the following criteria will be eligible for entry into this study: Patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry Patient may have started imatinib prior to study entry but has not received more than days of imatinib Grade or greater rash of any cause at time of study entry Use of over the counter (OTC) PPIs within months prior to study entry\r\n* Esomeprazole (Nexium)\r\n* Lansoprazole (Prevacid)\r\n* Omeprazole (Prilosec, Zegerid) Use of orlistat or any other known FASN inhibitor within months prior to study entry Must not have received any biological modifier within days of entry on to this study At the time of study entry, blood counts performed within weeks prior to study entry must meet the following criteria: Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within days prior to study entry according to institutional standards for women of childbearing potential.) Progressive cancer at the time of study entry Use of tumor necrosis factor (TNF) alpha inhibitors within four weeks prior to study entry Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or MRI) within days prior to study entry. If suspicious or abnormal, FNA or core biopsy is recommended. Findings of these evaluations will be used to define the nodal status prior to study entry according to the following criteria: Excisional biopsy or lumpectomy performed prior to study entry. Baseline tumor measurements must be documented from tests within days of study entry; other non-laboratory tests must be performed within days of study entry Laboratory tests required for eligibility must be completed within days prior study entry; baseline tumor measurements must be documented from tests within days of study entry; other non-laboratory tests must be performed within days of study entry Patients taking sertraline at the time of study entry will not be eligible for the study The subject has tested positive for the Clostridium difficile toxin within days of study entry. Any of the following prior therapies:\r\n* Chemotherapy =< weeks prior to study entry\r\n* Immunotherapy =< weeks prior to study entry\r\n* Biologic therapy =< weeks prior to study entry\r\n* Extensive abdominal surgery if it includes enterotomy(ies) =< weeks prior to study entry; (NOTE: this criterion does not apply to placement of the peritoneal Port-A-Cath or lysis of adhesions at the time of study entry)\r\n* Any viral or gene therapy prior to study entry Initial diagnosis of metastatic disease must have occurred ? weeks prior to entry in the study. Hepatic inclusion within weeks of entry Normal mammogram of unaffected breast within months prior to study entry No other therapy (i.e. chemotherapy, interferon) for weeks prior to study entry, or cladribine for months prior to study entry Patients on -alpha reductase inhibitors such as finasteride or dutasteride must stop medication at least days prior to study entry. Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study Has distant metastatic disease on imaging or staging laparoscopy at the time of study entry Patients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must have been adequately treated for at least weeks before study entry; subjects with bacteremia must have documented negative blood cultures prior to study entry Imaging evaluations necessary to establish eligibility for study entry must be done within three () weeks prior to registration All other evaluations necessary to establish eligibility for study entry must be done within two () weeks prior to registration Subject who have received ferumoxytol within weeks of study entry Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study Subject who have received ferumoxytol within weeks of study entry History of acute urinary retention within months of study entry; The investigator must document that he/she believes the subject would not benefit from additional BCG treatment at the time of study entry Chemotherapy must not have been received within weeks of entry onto this study Previous intravesical therapy within months of study entry. Symptomatic brain metastases or meningeal tumors or other uncontrolled metastases in the central nervous system (CNS) unless the patient\r\n* Is > months from definitive therapy,\r\n* Has a negative imaging study within weeks before study entry (informed consent form [ICF] signature for full study) and\r\n* Is clinically stable with respect to the tumor at the time of study entry Hyperleukocytosis (leukocytes ? x /L) at study entry. These patients may be treated with hydroxyurea according to routine practice, and enroll in the study when the leukocyte count falls below x /L. Appropriate stage for protocol entry including no clinical evidence for distant metastases based upon the following minimum diagnostic workup:\r\n* History/physical examination, documentation of weight and Zubrod performance status - within days prior to study entry\r\n* Right and left mammography within days of diagnostic biopsy establishing diagnosis The etiology of abnormal bilirubin and transaminase levels should be evaluated prior to study entry Radiographic or cytologic evidence of leptomeningeal or multifocal disease at any time prior to study entry Participants must not have an invasive infection at time of protocol entry No abnormalities on pre-entry electrocardiogram, obtained within days prior to being registered on study Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following: Subjects with bacteremia must have documented negative blood cultures prior to study entry Fully resected disease at study entry (residual CIS acceptable) Platelets > x ^/L within days of study entry We will allow XRT prior to study entry to other sites, with no washout period, allowed prior to study entry as long as at least one measurable sites of disease is kept unirradiated Biologic therapy (anti-neoplastic)\r\n* Must not have received oral tyrosine kinase inhibitors (other than dasatinib) or other similar agents within weeks of the study entry and all toxicities must have resolved to < grade prior to enrollment\r\n* Must not have received bevacizumab or other monoclonal antibody therapy within weeks of study the entry Use of zidovudine as part of the HAART regimen (a drug substitution for zidovudine at the time of study entry is allowed) At the time of study entry, blood counts performed within weeks prior to study entry must meet the following criteria: Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within days prior to study entry according to institutional standards for women of childbearing potential.) Patients receiving erythropoietin (darbepoetin, epoetin alfa) must be on a stable dose and with stable transfusion requirement or hemoglobin level during the weeks prior to study entry Tumor not suitable for resection at the time of study entry; (transplant eligible patients are allowed) Histologically confirmed AML by hematopathology review performed within four weeks prior to study entry Allogeneic or autologous transplant for AML with infusion of stem cells within days of study entry or on active immunosuppressive therapy for (GVHD) within weeks before study entry Patients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least weeks before study entry; patients with bacteremia must have documented negative blood cultures prior to study entry Skin biopsy performed at least days and no longer than weeks from the time of initial entry into the study Participants must not have an invasive infection at time of protocol entry All patients must undergo pre-treatment evaluation of tumor extent prior to study entry through imaging studies and clinical examinations, including computed tomography (CT) and/or magnetic resonance imaging (MRI) of skull base, brain and neck within days prior to study entry; physical examination +/- nasal endoscopy within days prior to study entry; and CT of the chest within days prior to study entry Must not have received any biological modifier within days of entry on to this study No other therapy (i.e. chemotherapy, interferon) for weeks prior to study entry, or cladribine for months prior to study entry, unless progressive disease more than months after cladribine is documented Patients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have received either agent within days of entry are ineligible Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within days prior to study entry according to institutional standards for women of childbearing potential.) Did not receive any investigational treatment for at least days prior to study entry Completed autologous BMT (if received) at least months prior to study entry; completed allogeneic BMT (if received); at least months prior to study entry Consultations: all patients should be evaluated by a surgeon prior to study entry Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least days prior to study enrollment Subjects with bacteremia must have documented negative blood cultures prior to study entry Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study Patients with ureteral obstruction (i.e., hydronephrosis identified on CT imaging) must undergo stent or nephrostomy tube placement prior to study entry Diabetic patients requiring insulin for glucose control at the time of study entry Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: Must not have received within weeks of entry onto this study ( weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least days since the completion of therapy with a biologic agent; at least weeks for biologic agents with a long half life, such as antibodies\r\n* External beam radiation therapy (XRT): Must not have received craniospinal radiotherapy within weeks prior to study entry; the tumor designated as measurable for protocol purposes must not have received radiation within weeks prior to study entry); focal radiation to areas of symptomatic metastatic disease must not be given within days of study entry\r\n* Stem cell transplant (SCT): For autologous SCT, >= months must have elapsed prior to study entry\r\n* Study specific limitations on prior therapy:\r\n** Patients must not have previously received bevacizumab, irinotecan, temozolomide or other anti-vascular endothelial growth factor (VEGF) inhibitor\r\n** Patients must not be taking enzyme-inducing antiepileptic medicines within week of study entry Use of zidovudine or cobicistat as part of the HAART regimen (a drug substitution at the time of study entry is allowed) Any acute, inter-current infection that may interfere with planned protocol treatment; participants with mycobacterium avium will not be excluded from study entry; chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met Off all myelofibrosis (MF)-directed therapy including investigational agents for at least weeks prior to study enrollment and recovered from all toxicities; patient who has been on stable dose of ruxolitinib and has received ruxolitinib =< months prior to the study entry will be considered potentially eligible for the study with the caveat that there is no evidence of loss of response (> cm increase in spleen size from the nadir) Diagnosed less than years prior to entry on trial previous intravesical BCG therapy, which can be given at least weeks before the diagnostic biopsy required for entry into the study The presence of any of the following will exclude a subject from enrollment into the Induction and Maintenance parts of the study (except if specified at study entry only): Proliferative disease (WBC > x /L) (confirmed at time of study entry prior to first dose) Fludarabine or Campath within months prior to study entry Patients must not have prior history of desquamating rash from thalidomide at time of study entry History of ischemic cardiac disease that has occurred within months prior to study entry. Hgb < g/L, have received ? units PRBC in the weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib; Patients must also have documented evidence of PD during or within days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease). have had unprotected sexual intercourse within days before study entry, Normal carcinoembryonic antigen (CEA) prior to study entry Patients who have received any treatment with ibrutinib prior to study entry Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to hours before study entry in core Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of -% at study entry Patients who have received any treatment with SGN- prior to study entry Patients must not have received any prior chemotherapy, radiation therapy, biologic therapy, or bone marrow transplant; surgery and dexamethasone are permitted prior to study entry; in patients who require anticonvulsants prior to study entry, it is permissible to start VPA, but trough VPA concentration must be repeated within hours of study entry Patients with abnormality of the tibial metaphyseal plate on plain x-ray prior to study entry are not eligible Concurrent treatment with estrogens or progestins; patients must stop these drugs at least two weeks prior to study entry Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed > weeks prior to study entry; for such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry Previous chemotherapy and/or investigational agents are allowed if completed > weeks prior to study entry (> weeks if last regimen contained bis-chloroethyl nitrosourea [BCNU] or mitomycin C); for patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry Patients who have completed sipuleucel-T (Provenge ) treatment within days of study entry. Patient has: random glucose > mg/dl or is taking an oral hypoglycemic agent or insulin at the time of study entry Diabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last weeks) at the time of study entry Diabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last weeks) at the time of study entry Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry. Patients will be registered on study based on the local exam under anesthesia (EUA) done for diagnostic purposes prior to study entry; the EUA done at study entry should be done within days prior to study entry Patient should have a normalized or normal uric acid level prior to study entry History of arterial or embolic events (within months prior to study entry) Laboratory tests required for eligibility must be completed within days prior study entry; baseline tumor measurements and ECHO or MUGA must be documented from tests completed within days of study entry; other non-laboratory tests must be performed within days of study entry Patients with the following within the last months prior to registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study Participants must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention; participants may have a history of prior malignancy, provided that he/she has not had any chemotherapy within days of study entry AND that life expectancy exceeds years at the time of study entry Patients treated with interferon or other anti-HCV therapy within months prior to study entry Subjects with bacteremia must have documented negative blood cultures prior to study entry Treatment within the last days with a drug that has not received regulatory approval for any indication at the time of study entry Participants must have baseline echocardiogram and pulmonary function tests within months prior to study entry Vaginal bleeding of unknown etiology within months of study entry Patient has been treated with nelfinavir within months of entry into this trial Have received treatment within the last days prior to study entry with any drug that has not received regulatory approval for an indication at the time of study entry Patient has at least years of nilotinib treatment prior to study entry. Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study Oral retinoid therapy for any indication within weeks of study entry Prior radiation therapy (RT) within months of study entry Note: laboratory tests required for eligibility must be completed within weeks prior to study entry; baseline measurements in the CNS must be documented from tests within days of study entry; other non-laboratory tests must be performed as indicated For bevacizumab-naive patients (groups and ) a minimum of months must have elapsed since completion of radiation therapy for study entry, and there is no minimum time since completion of last chemotherapy; for bevacizumab-exposed patients (groups and ) no minimum time since completion of last radiation therapy, biologic agents, or chemotherapy will be required for study entry Systemic chemotherapy within weeks prior to study entry (signing consent form) Radiation therapy for splenomegaly within months prior to study entry Previous treatment for APL, except tretinoin, which may be given for up to days prior to study entry Recovered from side effects that might interfere with the protocol therapy and:\r\n* >= weeks must have elapsed from last radiation treatment to time of study entry\r\n* >= weeks must have elapsed from the last chemotherapy administration to time of study entry\r\n* >= weeks from the last immunotherapeutic agent administered to time of study entry Study participant must use birth control measure prior to study entry (during screening), during study participation, and for weeks after bevacizumab is discontinued Any chemotherapy and/or radiation therapy received =< months of study entry and any immunotherapy received =< months of study entry (with the execption of Bacillus Calmette-Guerin [BCG] treatment) Imaging evaluations necessary to establish eligibility for study entry must be done within three () weeks prior to registration; all other evaluations necessary to establish eligibility for study entry must be done within two () weeks prior to registration; in the event that the patients condition deteriorates (performance score < ) within hours prior to the injection the patient is no longer eligible to receive HSV injection Patients must have measurable disease as defined by palpable lesion with both diameters >= cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension >= cm; bilateral mammogram and clip placement is required for study entry; baseline measurements of the indicator lesions must be recorded on the Patient Registration Form; to be valid for baseline, the measurements must have been made within the days if palpable; if not palpable, a mammogram or magnetic resonance imaging (MRI) must be done within days; if palpable, a mammogram or MRI must be done within months prior to study entry; if clinically indicated, x-rays and scans must be done within days of study entry Patient must be able to be treated with remestemcel-L within days of study entry. Congenital TTP (known at the time of study entry). Individuals must have been on a stable dose of ruxolitinib for at least weeks prior to study entry Chemotherapy or other investigational anticancer therapeutic drugs within week prior to study entry unless AEs have resolved and there is no interference with the assessment of efficacy or safety; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to hours before study entry. Patients with prior bone marrow or stem cell transplant, considered for inclusion, should be discussed with the medical monitor first. Patients may receive hydroxyurea, low-dose cytarabine and/or glucocorticoids to control peripheral blood leukemic cell counts at study entry Diagnostic examination under anesthesia (EUA) must be performed within days prior to study entry Symptomatic metastatic brain or meningeal tumors unless the patient is > months from definitive therapy, has a negative imaging study within weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Received bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within weeks prior to study entry Must have known MGMT methylation and IDH mutation status to be screened for study entry. Donor must not have an active infection at the time of study entry. Patients with cirrhosis must have had esophagogastric endoscopy within the previous months prior to study entry for the assessment of varices; if the patient has not had this done they must be willing to undergo this procedure prior to study entry Because the effects of ofatumumab on fetuses and nursing infants are not known, the following are ineligible for study entry: Measurable disease at the time of study entry Patients must have measurable disease as defined by palpable lesion with both diameters >= cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension >= cm; bilateral mammogram and clip placement is required for study entry; baseline measurements of the indicator lesions must be recorded on the patient registration form; to be valid for baseline, the measurements must have been made within the days if palpable; if not palpable, a mammogram or magnetic resonance imaging (MRI) must be done within days; if palpable, a mammogram or MRI must be done within months prior to study entry; if clinically indicated, x-rays and scans must be done within days of study entry The participant has metastatic disease at the time of study entry Chemotherapy or other investigational anticancer therapeutic drugs within week prior to study entry. AEs from prior therapy must have resolved or stabilized so that there is no interference with the assessment of efficacy or safety; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to hours before study entry. Patients with prior bone marrow or stem cell transplant, considered for inclusion, should be discussed with the medical monitor first. Fludarabine or Campath within months prior to study entry Has distant metastatic disease on imaging or staging laparoscopy at the time of study entry Prior biologic or immunologic therapy =< weeks prior to study entry Patients who have received any treatment of ponatinib prior to study entry Uncontrolled angina within months prior to study entry; In remission at time of study entry, may be receiving chemoprevention Presence of do not resuscitate (DNR)/do not intubate (DNI) orders at study entry Use of finasteride or dutasteride within weeks or months, respectively, of study entry There is evidence of the disease at the time of entry into the trial If patients are on opioids for the treatment of cancer pain, they must have had no dose changes (> %) for at least hours prior to study entry; change in opioid dose after study entry is allowed Patients may have started consolidative chest irradiation by the time of study entry Time from completion of cancer treatment to study entry: >= years Presence of hot flashes for > days prior to study entry If patients are on opioids for the treatment of cancer pain, they must have had no major dose change (> %) for at least hours prior to study entry; change in opioid dose after study entry is allowed Non-randomized pilot cohort:\r\n* Concurrent chemotherapy (initiated within months of study entry) or planned chemotherapy within months of study entry Vaginal dryness or dyspareunia must be present for at least two months prior to study entry The patient has a clinical negative node status at the time of study entry (i.e. T-, M, tumor staging criteria) Use of allopurinol within hours of the study entry Subjects who are taking drugs known to interact with posaconazole and that may lead to life-threatening side effects (terfenadine, cisapride, and ebastine at entry or within hours before entry, or astemizole at entry or within days before entry) Subjects who are taking drugs known to lower the serum concentration/efficacy of posaconazole: cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, and isoniazid at entry or within hours before entry Presence of hot flashes for >= month prior to study entry Baseline mammogram performed within days prior to study entry, done on a digital mammography machine, that are reported as normal or benign. Participants must be willing to abstain from drinking green tea or taking supplements containing green tea or green tea compounds, for the duration of the investigation and for days prior to study entry\r\n* (Please note that patients with a treated TN or TN squamous carcinoma and who do not have a pre-malignant measurable lesion at the time of study entry will not be subjected to a biopsy but will have cytobrush samples taken as specified in the protocol) Completion of first-line radiation at least months prior to study entry. History of DHA supplementation > mg/day in the month preceding study entry Patients on aromatase inhibitors other than letrozole at study entry. The patient has a clinical negative node status at the time of study entry (i.e., Tis-, N, M) Subject who have received ferumoxytol within weeks of study entry Subject who have received ferumoxytol within weeks of study entry Subject who have received ferumoxytol within weeks of study entry The patient must agree at the time of study entry to undergo clinically indicated biopsy(ies) or -month period of follow-up, as needed, to resolve the etiology of their IPN(s) or lung mass(es) Patients having undergone prior hysterectomy will be eligible provided that they meet the other requirements for entry into this study After entry into the study, participants agree to be followed for up to weeks after the final infusion of ferumoxytol Patient must not have received craniospinal radiotherapy or involved field radiotherapy to the local tumor (and/or tumor designated as measurable for protocol purposes) =< weeks prior to study entry; focal radiation to areas of symptomatic metastatic disease must not be given within days of study entry Replacement hormone therapy initiated before study entry is permitted Replacement hormone therapy initiated before study entry is permitted N and M at the time of study entry. Men and women diagnosed with CP-CML, on treatment with dasatinib for a minimum of years at the time of enrollment and in dasatinib-induced complete molecular remission ongoing for at least year prior to study entry. Patients with treated brain metastases are eligible if they are > weeks from therapy completion (including radiation and/or surgery), are clinically stable at the time of study entry and are not receiving corticosteroid therapy at the time of study entry has been diagnosed less than months before study entry and/or